WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202064
Description: Oglufanide disodium is t he disodium salt of a synthetic form of a naturally-occurring dipeptide consisting of L-glutamic acid and L-tryptophan with potential antiangiogenic and potential immunomodulating activities. Oglufanide inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitic C virus and intracellular bacterial infections. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
MedKoo Cat#: 202064
Name: Oglufanide disodium
Chemical Formula: C16H17N3Na2O5
Exact Mass: 333.13247
Molecular Weight: 377.3
Elemental Analysis: C, 57.65; H, 5.75; N, 12.61; O, 24.00
Oglufanide disodium is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: NSC 334073; Oglufanide; Thymogen; Timogen; IM 862.
IUPAC/Chemical Name: (S)-4-amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid
InChi Key: LLEUXCDZPQOJMY-AAEUAGOBSA-N
InChi Code: InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1
SMILES Code: O=C(O)CC[C@H](N)C(N[C@H](C(O)=O)CC1=CNC2=C1C=CC=C2)=O
The following data is based on the product molecular weight 377.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. National Center for Biotechnology Information. PubChem Compound Database; CID=158780, https://pubchem.ncbi.nlm.nih.gov/compound/158780 (accessed July 8, 2015).
Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by the privately-owned Brisbane biotech company Implicit Bioscience Pty Ltd in 2005. Oglufanide regulates the body's innate immune response to defeat invading germs and cancer cells. The drug is also under development by Implicit for severe respiratory diseases such as influenza (including pandemic disease) and ovarian cancer. Oglufanide has US Investigative New Drug status and Orphan Drug designation for cancer. see Company's news published in 2006.